Mark Stein
Impact in
- Pulmonary and Respiratory Medicine top 0.5%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Cancer Research top 1%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Prostate Cancer Treatment and Research 30
- Renal cell carcinoma treatment 23
- Prostate Cancer Diagnosis and Treatment 14
- Oncology 45
- Cancer Immunotherapy and Biomarkers 19
- Co-authors
- Robert S. DiPaola (26 shared papers)Eileen White (8 shared papers)Susan Goodin (8 shared papers)Kevin Bray (4 shared papers)Grace L. Lu‐Yao (5 shared papers)Yu‐Hsuan Joni Shao (4 shared papers)Simantini Eddy (3 shared papers)Charles G. Drake (5 shared papers)
- Journals
- Clinical Cancer Research (14 papers)Journal of Clinical Oncology (14 papers)Annals of Oncology (11 papers)Journal for ImmunoTherapy of Cancer (8 papers)Investigational New Drugs (7 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Mark Stein
151 papers receiving 8.6k citations
Mark Stein's Hit Papers
Peers
Comparison fields: 5 of 133
- Pulmonary and Respiratory Medicine 3.6k
- Cancer Research 1.6k
- Oncology 2.4k
- Immunology 876
- Molecular Biology 2.6k
Countries citing papers authored by Mark Stein
This map shows the geographic impact of Mark Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Stein more than expected).
Fields of papers citing papers by Mark Stein
This network shows the impact of papers produced by Mark Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Stein. The network helps show where Mark Stein may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Stein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 158 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Hit paper breakdown → | 2016 | 1297 |
| 2 | A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors Hit paper breakdown → | 2012 | 455 |
| 3 | Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma Hit paper breakdown → | 2012 | 398 |
| 4 | 2016 | 315 | |
| 5 | 2010 | 258 | |
| 6 | 2017 | 241 | |
| 7 | 2018 | 231 | |
| 8 | 2009 | 220 | |
| 9 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 218 |
| 10 | A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial Hit paper breakdown → | 2021 | 218 |
| 11 | 2017 | 201 | |
| 12 | 2017 | 183 | |
| 13 | 2017 | 183 | |
| 14 | 2018 | 151 | |
| 15 | 2012 | 136 | |
| 16 | 2016 | 136 | |
| 17 | 2010 | 135 | |
| 18 | 2017 | 131 | |
| 19 | 2019 | 125 | |
| 20 | 2009 | 116 |
About Mark Stein
Mark Stein is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Immunology and Surgery, having authored 158 papers that have together received 8.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (30 papers), Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (19 papers), Bladder and Urothelial Cancer Treatments (19 papers), Prostate Cancer Diagnosis and Treatment (14 papers), Immunotherapy and Immune Responses (10 papers), Cancer Genomics and Diagnostics (8 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.6k citations), Cancer Research (1.6k citations), Oncology (2.4k citations), Immunology (876 citations) and Molecular Biology (2.6k citations). Mark Stein has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Robert S. DiPaola, Eileen White, Susan Goodin, Kevin Bray, Grace L. Lu‐Yao, Yu‐Hsuan Joni Shao, Simantini Eddy, Charles G. Drake, Dmitri Dvorzhinski and Amit R. Mehta. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Journal for ImmunoTherapy of Cancer and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.